Current clinical efforts should therefore focus on monitoring carriers of ANK2 functional variants for arrhythmia and cardiomyopathy, along with symptomatic and treatment and control of co-morbidities (106). This evidence concerns the gene ANK2 and cardiac arrhythmia.